Immunohematology最新文献_第5页

Contents. 内容。

Immunohematology Pub Date : 2023-03-01 DOI: 10.21307/immunohematology-2023-001

引用次数: 0

To contributors to the 2022 issues. 致2022年问题的撰稿人。

Immunohematology Pub Date : 2022-12-01 DOI: 10.21307/immunohematology-2022-060

Margaret A Keller, Cynthia Flickinger

引用次数: 0

The KANNO blood group system. KANNO血型系统。

Immunohematology Pub Date : 2022-12-01 DOI: 10.21307/immunohematology-2022-053

H Ohto, M Uchikawa, S Ito, I Wada, K E Nollet, Y Omae, K Ogasawara, K Tokunaga

引用次数: 1

Contents. 内容。

Immunohematology Pub Date : 2022-12-01 DOI: 10.21307/immunohematology-2022-052

引用次数: 0

RHCE variant alleles and risk of alloimmunization in Brazilians. 巴西人RHCE变异等位基因与同种异体免疫风险

Immunohematology Pub Date : 2022-12-01 DOI: 10.21307/immunohematology-2022-054

C P Arnoni, T A P Vendrame, F S Silva, A J P Cortez, F R M Latini, L Castilho

{"title":"RHCE variant alleles and risk of alloimmunization in Brazilians.","authors":"C P Arnoni, T A P Vendrame, F S Silva, A J P Cortez, F R M Latini, L Castilho","doi":"10.21307/immunohematology-2022-054","DOIUrl":"https://doi.org/10.21307/immunohematology-2022-054","url":null,"abstract":"Variant RHCE alleles are found mainly in Afro-descendant individuals, as well as in patients with sickle cell disease (SCD). The most common variants are related to the RHCE*ce allele, which can generate partial e and c antigens. Although RHCE variant alleles have been extensively studied, defining their clinical significance is a difficult task. We evaluated the risk of RhCE alloimmunization as a consequence of partial antigens in patients with a positive phenotype transfused with red blood cell (RBC) units with the corresponding antigen. A retrospective study was performed with Brazilian patients, evaluating the number of antigen-positive transfused RBC units (incompatible due to partial antigen) in 27 patients with SCD carrying RHCE variant alleles who did not develop antibodies as well as evaluating the variants present in 12 patients with partial phenotype and correlated antibody (one patient with SCD and 11 patients with other pathologies). Two patients showed variant alleles with molecular changes that had not yet been described. Variant RHCE alleles were identified in a previous study using molecular methods. RHCE*ceVS.01 was the most frequent allele found among the patients without antibodies. Six patients with partial c antigen had a mean of 3.8 c+ RBC units transfused, and 10 patients with partial e antigen were exposed for a mean of 7.2 e+ RBC units. Among the variant alleles found in alloimmunized patients, the most frequent was RHCE*ceAR, which was found in five patients; the antibodies developed were anti-hrS and/or anti-c. Our results showed that RHCE*ceVS.01 is indeed the most frequent variant allele in our cohort of patients with SCD, but the partial antigens that were identified have low risk of alloimmunization. RHCE*ceAR is the most impactful variant in the Brazilian population with high risk of alloimmunization and clinically significant anti-hrS formation.","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"38 4","pages":"123-129"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yes, MAM: how the cancer-related EMP3 protein became a regulator of erythropoiesis and the key protein underlying a new blood group system. 是的，MAM:癌症相关的EMP3蛋白如何成为红细胞生成的调节因子和新血型系统的关键蛋白。

Immunohematology Pub Date : 2022-12-01 DOI: 10.21307/immunohematology-2022-055

M D Ilsley, J R Storry, M L Olsson

{"title":"Yes, MAM: how the cancer-related EMP3 protein became a regulator of erythropoiesis and the key protein underlying a new blood group system.","authors":"M D Ilsley, J R Storry, M L Olsson","doi":"10.21307/immunohematology-2022-055","DOIUrl":"https://doi.org/10.21307/immunohematology-2022-055","url":null,"abstract":"The MAM blood group system (International Society of Blood Transfusion [ISBT] 041) consists of one high-prevalence antigen to date, first detected in a 31-year-old woman during her third pregnancy. Epithelial membrane protein 3 (EMP3) was recently identified as the gene coding the MAM antigen. Six unique genetic variants have been described in EMP3 in 11 MAM- individuals. EMP3 is an 18-kDa glycoprotein with a large extracellular domain containing at least one N-glycosylation site. The normal function of EMP3 is still unclear, but ex vivo culture of erythropoietic progenitor cells from MAM- individuals shows an increased yield of reticulocytes, suggesting that EMP3 acts as a brake during normal erythropoiesis. EMP3 is abundant on different cell types, including many epithelial tissues and blood cells. Interestingly, EMP3 expression has been suggested as a prognostic marker for a number of cancer types, both for good and poor prognoses. EMP3 may act as a tumor suppressor or an oncogene in different cancer contexts. The protein appears to interact with other cell surface receptors and affects the downstream signaling and function of these proteins. MAM- red blood cells express low levels of CD44 and, consequently, the antigens of the Indian blood group system are only weakly expressed. Clinically, the MAM blood group antigen is important with regard to blood transfusion and pregnancy. Anti-MAM can cause severe hemolytic disease of the fetus and newborn in some pregnancies but have little to no effect in other pregnancies. Cases are typically not detected until problems occur during pregnancy, making the availability of compatible blood a challenge.","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"38 4","pages":"130-136"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10744114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare case of clinically significant anti-c in a 1-year-old pediatric patient. 1岁儿童罕见临床显著抗-c。

Immunohematology Pub Date : 2022-12-01 DOI: 10.21307/immunohematology-2022-057

Sheetal Malhotra, Ashish Jain, Ratti Ram Sharma, Srinivasan Peyam

引用次数: 0

Use of e^VAR and anti-e^VAR as interim terms. 使用eVAR和反eVAR作为临时条款。

Immunohematology Pub Date : 2022-12-01 DOI: 10.21307/immunohematology-2022-058

Sandra Nance

引用次数: 0

Post COVID-19 vaccination and adverse events: correspondence. COVID-19后疫苗接种和不良事件:对应。

Immunohematology Pub Date : 2022-12-01 DOI: 10.21307/immunohematology-2022-059

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

引用次数: 0

Enzyme treatment of red blood cells: use of ficin and papain. 红血球的酶治疗:使用菲克林和木瓜蛋白酶。

Immunohematology Pub Date : 2022-09-22 Print Date: 2022-09-01 DOI: 10.21307/immunohematology-2022-048

B Bruce

引用次数: 2